SCHEMBL5507754

SCHEMBL5507754

CCOc1cc2c(cc1OC)C(c1ccc(N3CCOCC3)cc1)=NC1CCC(O)CC21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 2/20 0.51
PDE4A P27815 1/20 0.51
PDE4B Q07343 1/20 0.51
PDE4C Q08493 1/20 0.51
ALDH1A1 P00352 7/20 0.41
HPGD P15428 5/20 0.41
HIF1A Q16665 1/20 0.41
CHEK1 O14757 2/20 0.38
FYN P06241 1/20 0.38
MAPT P10636 7/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
LMNA P02545 4/20 0.37
TP53 P04637 1/20 0.37
MAPK1 P28482 2/20 0.37
GAA P10253 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
IL2 P60568 1/20 0.37
MAP4K1 Q92918 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5503540 0.92 PDE4D (0.55) PDE4DPDE4APDE4BPDE4CALDH1A1
SCHEMBL2263482 0.90 PDE4A (0.47) PDE4DPDE4APDE4BPDE4CALDH1A1
SCHEMBL5479126 0.85 PDE4D (0.52) PDE4DPDE4APDE4BPDE4CMAPT
SCHEMBL6390285 0.85 PDE4D (0.52) PDE4DPDE4APDE4BPDE4CMAPT
SCHEMBL2268015 0.84 PDE10A (0.49) PDE4DPDE4APDE4BPDE4CMAP4K1
SCHEMBL2265927 0.84 PDE4D (0.51) PDE4DPDE4APDE4BPDE4CALDH1A1
SCHEMBL5506282 0.83 PDE4D (0.48) PDE4DPDE4APDE4BPDE4CCYP3A4
SCHEMBL5510203 0.83 PDE4D (0.48) PDE4DPDE4APDE4BPDE4CCYP3A4
SCHEMBL5503762 0.83 PDE4D (0.48) PDE4DPDE4APDE4BPDE4CCYP3A4
SCHEMBL5067976 0.83 PDE4D (0.51) PDE4DPDE4APDE4BPDE4CALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191413-A1 Novel heterocycle-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors ATLANTA PHARMA AG (DE) 2007-08-16 US claimed
EP-1812400-A1 NOVEL HETEROCYCLYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS Altana Pharma AG (DE) 2007-08-01 EP claimed
WO-2005090311-A1 NOVEL HETEROCYCLYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-29 WO claimed
US-20070191413-A1 Novel heterocycle-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors ATLANTA PHARMA AG (DE) 2007-08-16 US disclosed
EP-1812400-A1 NOVEL HETEROCYCLYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS Altana Pharma AG (DE) 2007-08-01 EP disclosed
WO-2005090311-A1 NOVEL HETEROCYCLYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191413-A1 Novel heterocycle-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors PDE4A, PDE4B, PDE4C PDE4D 4/4885PDE4A 1/4885PDE4B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.